Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10040912HBVENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TVIS30003476HIVENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TVIS30008273HIVENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TVIS30056472HIVENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TVIS30056473HIVENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TVIS30056474HIVENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TVIS30056475HIVENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TVIS20032084HPVENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TVIS20036520HPVENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TVIS44008532HTLV-1ENSG00000077097.17protein_codingTOP2BNoNo7155Q02880
TCGA Plot Options
Drug Information
GeneTOP2B
DrugBank IDDB00694
Drug NameDaunorubicin
Target IDBE0002425
UniProt IDQ02880
Regulation Typeinhibitor
PubMed IDs6380596; 1963303
CitationsAubel-Sadron G, Londos-Gagliardi D: Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie. 1984 May;66(5):333-52.@@Zunino F, Capranico G: DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des. 1990 Nov;5(4):307-17.
GroupsApproved
Direct ClassificationAnthracyclines
SMILESCOC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
Pathways
PharmGKBPA449212
ChEMBLCHEMBL178